Bicara Therapeutics Inc. Common Stock (BCAX) Insider Trading
- $34,254,000.00
- $3,333,443.07
- April 21, 2026
- Claire Mazumdar
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| April 21, 2026 | CFO | 9,200 | $23.00 | Sell | $211,600.00 | |
| April 20, 2026 | CEO | 15,000 | $23.61 | Sell | $354,150.00 | |
| April 15, 2026 | COO | 12,500 | $23.01 | Sell | $287,625.00 | |
| March 23, 2026 | CFO | 9,200 | $18.52 | Sell | $170,384.00 | |
| March 20, 2026 | CEO | 1,596 | $18.95 | Sell | $30,244.20 | |
| March 19, 2026 | CEO | 6,905 | $18.78 | Sell | $129,675.90 | |
| March 18, 2026 | CEO | 6,499 | $18.84 | Sell | $122,441.16 | |
| March 16, 2026 | COO | 12,500 | $19.66 | Sell | $245,750.00 | |
| March 9, 2026 | CEO | 36,766 | $19.17 | Sell | $704,804.22 | |
| March 6, 2026 | CEO | 3,817 | $18.75 | Sell | $71,568.75 | |
| March 5, 2026 | CEO | 1,786 | $18.74 | Sell | $33,469.64 | |
| March 4, 2026 | CFO | 2,963 | $18.25 | Sell | $54,074.75 | |
| March 4, 2026 | Insider | 16,300 | $18.52 | Sell | $301,876.00 | |
| March 4, 2026 | CEO | 2,631 | $18.73 | Sell | $49,278.63 | |
| March 3, 2026 | Insider | 200 | $18.45 | Sell | $3,690.00 | |
| March 3, 2026 | CFO | 13,555 | $18.22 | Sell | $246,972.10 | |
| March 3, 2026 | COO | 17,392 | $18.16 | Sell | $315,838.72 | |
| Sept. 17, 2024 | Major Shareholder | 70,000 | $18.00 | Buy | $1,260,000.00 | |
| Sept. 16, 2024 | Director | 1,833,000 | $18.00 | Buy | $32,994,000.00 |
Insiders are both buying and selling Bicara Therapeutics Inc. Common Stock stock.
The insider traders at Bicara Therapeutics Inc. Common Stock are: Claire Mazumdar, Ivan Hyep, Ryan Cohlhepp, David Raben, James E Flynn, and Ra Capital Management, L.P.
The most active insider trader at Bicara Therapeutics Inc. Common Stock is Claire Mazumdar with 8 trades.
Claire Mazumdar has sold the most Bicara Therapeutics Inc. Common Stock stock with a total value of $1,849,782.50.
Ra Capital Management, L.P. has bought the most Bicara Therapeutics Inc. Common Stock stock with a total value of $65,988,000.00.
The most recent insider trade for Bicara Therapeutics Inc. Common Stock was on April 21, 2026.
The single biggest insider buy for Bicara Therapeutics Inc. Common Stock was from Ra Capital Management, L.P. with a total value of $32,994,000.00 on Sept. 16, 2024.
The single biggest insider sell for Bicara Therapeutics Inc. Common Stock was from Claire Mazumdar with a total value of $704,804.22 on March 9, 2026.